Trial Profile
Effects of an angiotensin receptor antagonist candesartan versus a calcium channel blocker amlodipine on microvascular rarefaction endothelial dysfunction and microalbuminuria in essential hypertension.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Oct 2022
Price :
$35
*
At a glance
- Drugs Candesartan cilexetil (Primary) ; Amlodipine
- Indications Essential hypertension
- Focus Pharmacodynamics
- Acronyms CAMIRA
- 20 Aug 2014 Status changed from recruiting to completed as reported by United Kingdom Clinical Research Network record.
- 25 Jan 2014 Accrual to date is 45% according to United Kingdom Clinical Research Network.
- 24 Oct 2013 Accrual to date is 43% according to United Kingdom Clinical Research Network.